Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities: 2016-2025

Historic Other Non-Current Liabilities for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Sep 2025 value amounting to $763.7 million.

  • Ultragenyx Pharmaceutical's Other Non-Current Liabilities fell 7.95% to $763.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $763.7 million, marking a year-over-year decrease of 7.95%. This contributed to the annual value of $819.8 million for FY2024, which is 4.93% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Other Non-Current Liabilities is $763.7 million, which was down 2.43% from $782.7 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Other Non-Current Liabilities' 5-year high stood at $886.5 million during Q1 2023, with a 5-year trough of $340.2 million in Q1 2021.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $842.2 million (2024), whereas its average is $835.2 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 149.27% in 2023, then declined by 7.95% in 2025.
  • Ultragenyx Pharmaceutical's Other Non-Current Liabilities (Quarterly) stood at $351.8 million in 2021, then soared by 148.86% to $875.4 million in 2022, then dropped by 1.50% to $862.3 million in 2023, then fell by 4.93% to $819.8 million in 2024, then dropped by 7.95% to $763.7 million in 2025.
  • Its last three reported values are $763.7 million in Q3 2025, $782.7 million for Q2 2025, and $794.0 million during Q1 2025.